Results 101 to 110 of about 28,175 (193)
American Journal of Hematology, Volume 101, Issue 9, Page 2288-2296, September 2026.ABSTRACT Dordaviprone is a first‐in‐class small‐molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell ...
Vijaya Raj Bhatt +8 more
wiley +1 more source
1693P Efficacy of corticosteroids in the treatment of chemotherapy-induced thrombocytopenia [PDF]
Annals of Oncology, 2021 A. Sbrana +5 more
openaire +1 more source
Primary Peritoneal Perivesical Hemangiosarcoma in 16 Dogs (2020–2024)
Veterinary Medicine and Science, Volume 12, Issue 5, September 2026.Primary peritoneal perivesical hemangiosarcoma in dogs may represent a distinct anatomical presentation of visceral hemangiosarcoma. Despite a high metastatic rate and guarded prognosis, multimodal treatment combining surgery and chemotherapy significantly improved progression‐free and disease‐specific survival compared with chemotherapy alone ...
Jose Roca +3 more
wiley +1 more source
Treatment of chemotherapy-induced thrombocytopenia with monotherapy versus combination therapy: the devil is in the details. [PDF]
Res Pract Thromb Haemost, 2023 Al-Samkari H.
europepmc +1 more source
Emerging Techniques in Minimally Invasive Surgery in Hematologic Malignancies
European Journal of Haematology, Volume 117, Issue 3, Page 682-690, September 2026.ABSTRACT Hematologic malignancies represent the most common cancers in children. While the mainstays of treatment are chemotherapy and potentially hematopoietic stem cell transplant, minimally invasive surgery (MIS) has a role in the diagnosis and management of complications related both to disease and therapy as well as common pediatric surgical ...
Alejandro Chara +3 more
wiley +1 more source
Pediatric Blood &Cancer, Volume 73, Issue 8, August 2026.ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta +6 more
wiley +1 more source
Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis. [PDF]
BMC Pharmacol Toxicol, 2023 Chen W, Liu Y, Li L, Zeng X.
europepmc +1 more source
Cancer Innovation, Volume 5, Issue 4, August 2026.Antiangiogenic‐based regimens demonstrated superior efficacy compared to chemotherapy alone in heavily pretreated MBC patients, with manageable AEs. ABSTRACT Background The prognosis for metastatic breast cancer (MBC) remains poor, and treatment options are limited for patients with heavily pretreated disease. Although antiangiogenic agents may provide
Yuanyi Wang +6 more
wiley +1 more source
Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors. [PDF]
Res Pract Thromb Haemost, 2023 Xia X +7 more
europepmc +1 more source
A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer
Cancer Medicine, Volume 15, Issue 8, August 2026.ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy +10 more
wiley +1 more source